Financial Markets
Financial Determinants of Health
Patient behavior follows the path of least resistance, as patients are more compliant when they face fewer hurdles in their...
Read more
COVID’s K-Shaped Recovery
While most project an optimistic outlook for economic recovery post-pandemic, we find it to be fundamentally disjointed, revealing structural economic...
Read more
Healthcare Innovation is Evolutionary
The pandemic may have put an end to many things, but it only accelerated early stage funding into healthcare startups....
Read more
Medical Devices are for the Startups
Most new medical devices are designed and developed by startups, only to be acquired by larger medical device corporations when...
Read more
J&J COVID-19 Go-To-Market Strategy
Market entry may be a sprint, but market dominance is a marathon. And those who end up winning the market...
Read more
Microfinance in Modern Healthcare
Microfinance has changed the world for good, helping millions support their healthcare costs. But the future of modern healthcare depends less...
Read more
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
The Importance of Access Control in the Workplace
-
Detecting Hospital M&A Synergies Before They’re Announced: A Rate-Based Event Strategy
-
State Regulators and the Federal Data Gap: How MedPricer Fills What CMS Leaves Incomplete
-
Employer-Sponsored Insurance Is Breaking Down. Price Data Tells You Where It’s Happening First.
-
The Transparency Paradox: Why Publishing Prices Can Raise Them
